What Is a Vasoreactivity Test in PAH? Results Explained

Hearing that you “did not respond” to a medical test can be frightening, but in this case, it simply points your medical team toward the right medications. A negative vasoreactivity test means that high doses of standard calcium channel blockers (CCBs) are not the correct primary treatment for your idiopathic pulmonary arterial hypertension (IPAH). It does not mean your heart or lungs cannot improve, nor does it mean your condition is untreatable. Because you are a non-responder—like the vast majority of people with IPAH—your care team will rule out the high-dose CCB strategy and move directly to modern, PAH-specific medications designed to target your condition ^[1].

Important safety note: This result only affects the use of high-dose CCBs used to treat pulmonary arterial hypertension. If you are already taking a standard-dose blood pressure medication or a CCB for another condition (such as typical high blood pressure or an abnormal heart rhythm), do not stop, start, or change these medications without consulting your PAH specialist.

What is the Test and Who Gets It?

A vasoreactivity test is performed during a right heart catheterization (RHC). While the RHC itself is a necessary procedure to establish the diagnosis and severity of pulmonary hypertension, the vasoreactivity portion is specifically used for patients with suspected idiopathic, heritable, or certain drug-induced PAH ^[2]. It helps doctors decide if the patient is a candidate for high-dose CCB therapy; it does not diagnose the cause of the disease on its own.

During the procedure, the doctor measures the baseline pressures inside your heart and pulmonary arteries. Then, they administer a fast-acting, short-lived medication—most commonly inhaled nitric oxide, though inhaled iloprost or intravenous epoprostenol are sometimes used ^[1]. The team watches your monitors to see exactly how your heart and lung blood vessels react to the temporary medication ^[2].

The “Responder” Criteria

The test identifies the small group of patients whose lung blood vessels significantly relax in response to the temporary drug. To be considered a true “responder” eligible for high-dose CCB therapy, your body must meet three strict criteria during the test ^[2]:

• Your mean pulmonary artery pressure (mPAP) must drop by at least 10 mmHg.
• Your mPAP must drop to an absolute value of 40 mmHg or less (≤ 40 mmHg).
• Your cardiac output (the amount of blood your heart is pumping) must stay the same or increase.

If your numbers do not meet all three of these strict cutoffs, you are a “non-responder.” This is the expected outcome for most people with IPAH ^[1].

Why Non-Responders Shouldn’t Use High-Dose CCBs for PAH

Non-response indicates that high-dose CCB therapy is unlikely to provide a sustained benefit for your pulmonary pressures ^[2]. For most patients with PAH, taking high-dose CCBs can actually be dangerous. These drugs are designed to lower systemic (body-wide) blood pressure, and they can weaken the pumping strength of the heart. If your lung pressures stay high but your heart’s pumping ability drops, it can lead to dangerous low blood pressure (hypotension) and significantly worsen right-sided heart failure ^[3][4].

Next Steps: Risk-Based PAH Therapies

Being a non-responder simply means your doctor will use medications that do more than just attempt to relax the blood vessels. You require modern PAH-specific therapies that target the complex disease pathways in the lungs ^[5].

Your treatment plan will not be determined by the vasoreactivity test alone. Instead, your specialist will conduct a comprehensive risk assessment based on your symptoms, right-ventricular heart function, and RHC hemodynamics ^[6].

• For appropriate low- or intermediate-risk patients, clinical guidelines generally recommend starting with initial combination therapy, often taking two oral medications simultaneously (such as an endothelin receptor antagonist combined with a PDE5 inhibitor) ^[5][7].
• For high-risk patients, or those with more advanced disease, treatment is more intensive and often involves starting three medications, which may include a continuous intravenous (IV) or subcutaneous infusion of a prostacyclin drug ^[5].

While these therapies do not cure PAH, they are designed to control the disease, improve symptoms, and reduce your overall risk level ^[6].

Warning Signs While Starting Treatment

As you begin PAH-specific therapies, close monitoring is essential. Call your PAH medical team immediately or seek emergency care if you experience:

• New or worsening fainting (syncope)
• Severe shortness of breath at rest
• Chest pain
• Rapid weight gain accompanied by severe swelling (edema)
• Symptoms of very low blood pressure, such as extreme dizziness or confusion
  (Note: If you are prescribed a continuous infusion therapy, any failure of the pump or IV line is a medical emergency that must be addressed immediately according to your clinic’s protocols.)